[Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
Usual treatments of metastatic renal cell carcinoma are not efficient. Phase II trials using Interferon alpha showed a low response rate (10 to 15%). We have conducted a phase I-II trial using a combination of Vinblastine and Recombinant alpha 2 A Interferon in 21 patients. The response rate is of 43% including 1 complete and 8 partial remissions, 5 stabilizations and 8 progressive diseases. In spite of important side effects, these results are promising.
Jacqmin
D
D
Service de Chirurgie Urologique, Hôpital de Hautepierre, CHU, Strasbourg.
Bergerat
J P
JP
Dufour
P
P
Bollack
C
C
Prévot
G
G
Jurascheck
F
F
Bailly
G
G
Degaris
S
S
Oberling
F
F
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use*
D007370:Interferon Type I; D011994:Recombinant Proteins; D014747:Vinblastine
Traitement médical du cancer du rein métastatique par l'association vinblastine-interferon alpha IIa recombinant. Résultat d'un essai de phase I-II.